Vobarilizumab
- Product Name
- Vobarilizumab
- CAS No.
- 1628814-88-9
- Chemical Name
- Vobarilizumab
- Synonyms
- Vobarilizumab;Vobarilizumab (anti-IL-6Ra);Research Grade Vobarilizumab;Research Grade Vobarilizumab (DHC36906);Anti-IL-6R Reference Antibody (Vobarilizumab-Fc)
- CBNumber
- CB93143888
- Formula Weight
- 0
- MOL File
- Mol file
Vobarilizumab Property
- form
- Liquid
- color
- Colorless to light yellow
Vobarilizumab Chemical Properties,Usage,Production
Uses
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis[1][2][3].
in vivo
Vobarilizumab (0.4-10 mg/kg, i.v.) inhibits hIL-6-induced inflammation in cynomolgus monkey[3].
Vobarilizumab (0.4-10 mg/kg, i.v.) shows a prolonged exposure through binding to serum albumin in cynomolgus monkeys[3].
| Animal Model: | hIL-6-induced inflammation in cynomolgus monkey[3] |
| Dosage: | 0.4 mg/kg, 2 mg/kg, or 10 mg/kg |
| Administration: | Intravenous injection (i.v.) |
| Result: | Inhibited the acute phase response parameters: plasma levels of C-reactive protein (CRP), fibrinogen and platelets. |
| Animal Model: | Cynomolgus monkeys[3] | ||||||||||||||||||||
| Dosage: | 0.4 mg/kg, 2 mg/kg, or 10 mg/kg | ||||||||||||||||||||
| Administration: | Intravenous injection (i.v.) | ||||||||||||||||||||
| Result: | Pharmacokinetic parameters of Vobarilizumab
|
References
[1] Kerschbaumer A, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020 Jun;79(6):744-759. DOI:10.1136/annrheumdis-2019-216656
[2] M. Van Roy, et al. FRI0021 Alx-0061, an anti-IL-6r nanobody for therapeutic use in rheumatoid arthritis, demonstrates in vitro a differential biological activity profile as compared to tocilizumab. Ann Rheum Dis. 2013. 72 (3).
[3] Van Roy M, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17(1):135. DOI:10.1186/s13075-015-0651-0
Vobarilizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Vobarilizumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 89689
- Advantage
- 60
- Tel
- 025-84523390 -127; 17705183659
- Fax
- 84523390
- sales@njleonbiotech.com
- Country
- China
- ProdList
- 5501
- Advantage
- 55
- Tel
- 025-58361106-805 15951641583
- Fax
- 025-58361106-806
- zhao.xu@njpeptide.com
- Country
- China
- ProdList
- 9979
- Advantage
- 55
- Tel
- meitaochem@126.com
- meitaochem@126.com
- Country
- China
- ProdList
- 19103
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24960
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9866
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 7062
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11972
- Advantage
- 58
- Tel
- 18229892877 13823398779
- 3062105966@qq.com
- Country
- China
- ProdList
- 5374
- Advantage
- 58